Day One Biopharmaceuticals Insider Sold Shares Worth $426,675, According to a Recent SEC Filing
TD Cowen Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating
TD Cowen analyst Marc Frahm maintains $Day One Biopharmaceuticals(DAWN.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.2% and a total average return of 14.3%
TD Cowen Keeps Their Buy Rating on Day One Biopharmaceuticals (DAWN)
Express News | Day One Biopharmaceuticals Inc Files for Offering of up to 12.1 Mln Shares by the Selling Stockholders - SEC Filing
A Great Week That Adds to Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) One-year Returns, Institutional Investors Who Own 56% Must Be Happy
Express News | Day One Biopharmaceuticals Inc : JP Morgan Adds Stock to Its Analyst Focus List
JP Morgan Maintains Overweight on Day One Biopharmaceutical, Lowers Price Target to $36
Express News | Day One Biopharmaceuticals Inc : JP Morgan Cuts Target Price to $36 From $38
Day One Biopharmaceuticals | 10-Q: Q2 2024 Earnings Report
Day One Biopharma Draws Double Upgrade at BofA on Ojemda Potential
Express News | Day One Biopharmaceuticals Inc : BofA Global Research Raises to Buy From Underperform
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $40 Price Target
BofA Securities Upgrades Day One Biopharmaceuticals(DAWN.US) to Buy Rating, Raises Target Price to $24
BofA Securities analyst Alec Stranahan upgrades $Day One Biopharmaceuticals(DAWN.US)$ to a buy rating, and adjusts the target price from $10 to $24.According to TipRanks data, the analyst has a
B of A Securities Upgrades Day One Biopharmaceutical to Buy, Raises Price Target to $24
Day One Biopharmaceutical Analyst Ratings
Oppenheimer Maintains Day One Biopharmaceuticals(DAWN.US) With Hold Rating
Oppenheimer analyst Matthew Biegler maintains $Day One Biopharmaceuticals(DAWN.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 40.4% and a total average return
A Quick Look at Today's Ratings for Day One Biopharmaceuticals(DAWN.US), With a Forecast Between $32 to $40
On Jul 31, major Wall Street analysts update their ratings for $Day One Biopharmaceuticals(DAWN.US)$, with price targets ranging from $32 to $40.TD Cowen analyst Marc Frahm maintains with a buy
Analysts Offer Insights on Healthcare Companies: Tilray (TLRY), Day One Biopharmaceuticals (DAWN) and Incyte (INCY)
Piper Sandler Remains a Buy on Day One Biopharmaceuticals (DAWN)